Physician profile
Jason Wayne Brown
NPI 1205850666
$4,926.33
in general payments reported to CMS, 2019-2025
41 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.55 · 2020: $60.09 · 2021: $255 · 2022: $43.71 · 2023: $2,749 · 2024: $872 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,375 · Food and Beverage: $1,918 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,375.00 |
| Food and Beverage | $1,917.92 |
| Education | $195.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,397.37 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $331.12 | 2020-2025 | Imfinzi, Calquence, Enhertu |
| Exelixis INC. | $307.64 | 2024-2025 | Cabometyx |
| Janssen Biotech, INC. | $253.00 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| E.R. Squibb & Sons, L.L.C. | $188.43 | 2020-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $152.25 | 2024-2025 | Libtayo |
| Abbvie INC. | $121.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $98.80 | 2024-2025 | |
| Adc Therapeutics America, INC. | $79.00 | 2025 | |
| Pfizer INC. | $72.31 | 2024-2025 | |
| Incyte Corporation | $72.30 | 2024-2025 | Jakafi, Niktimvo |
| Genentech USA, INC. | $71.71 | 2019-2025 | Venclexta, Tecentriq |
| Array Biopharma INC | $71.66 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $60.23 | 2021-2025 | Yescarta |
| Glaxosmithkline, LLC. | $59.69 | 2020-2025 | Jemperli, Zejula, Ojjaara |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.